Citigroup Forecasts Strong Price Appreciation for Corteva (NYSE:CTVA) Stock

Corteva (NYSE:CTVA) had its price target increased by equities research analysts at Citigroup from $83.00 to $85.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Citigroup’s target price would indicate a potential upside of 7.41% from the stock’s previous close.

A number of other research firms have also commented on CTVA. JPMorgan Chase & Co. lowered shares of Corteva from an “overweight” rating to a “neutral” rating and upped their price target for the company from $75.00 to $77.00 in a report on Thursday, February 5th. BNP Paribas Exane boosted their price objective on shares of Corteva from $74.00 to $77.00 in a research report on Wednesday. Oppenheimer upped their price objective on shares of Corteva from $86.00 to $89.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Zacks Research lowered shares of Corteva from a “strong-buy” rating to a “hold” rating in a report on Friday, February 20th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Corteva in a report on Wednesday, April 22nd. Fourteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $86.86.

Corteva Price Performance

NYSE CTVA traded down $2.64 on Thursday, reaching $79.14. 6,274,985 shares of the company’s stock traded hands, compared to its average volume of 4,024,688. The stock has a market cap of $53.13 billion, a PE ratio of 46.55, a P/E/G ratio of 2.88 and a beta of 0.59. Corteva has a 12 month low of $60.53 and a 12 month high of $85.63. The stock has a 50-day simple moving average of $80.66 and a 200 day simple moving average of $72.48. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.96.

Corteva (NYSE:CTVA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.18 by $0.32. Corteva had a net margin of 6.50% and a return on equity of 9.88%. The company had revenue of $4.91 billion during the quarter, compared to analysts’ expectations of $4.64 billion. During the same quarter in the prior year, the company earned $1.13 EPS. The firm’s revenue was up 11.0% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, research analysts predict that Corteva will post 3.62 earnings per share for the current year.

Insiders Place Their Bets

In other Corteva news, insider Brian Titus sold 8,311 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $76.55, for a total transaction of $636,207.05. Following the transaction, the insider owned 8,090 shares in the company, valued at approximately $619,289.50. This represents a 50.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.15% of the company’s stock.

Hedge Funds Weigh In On Corteva

A number of institutional investors have recently added to or reduced their stakes in CTVA. Brighton Jones LLC increased its stake in shares of Corteva by 307.2% in the 4th quarter. Brighton Jones LLC now owns 15,588 shares of the company’s stock worth $888,000 after acquiring an additional 11,760 shares in the last quarter. Woodline Partners LP grew its holdings in Corteva by 40.3% in the first quarter. Woodline Partners LP now owns 57,919 shares of the company’s stock worth $3,645,000 after purchasing an additional 16,644 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Corteva by 62.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,559 shares of the company’s stock valued at $191,000 after purchasing an additional 980 shares in the last quarter. Cresset Asset Management LLC increased its stake in shares of Corteva by 2.6% during the second quarter. Cresset Asset Management LLC now owns 7,063 shares of the company’s stock valued at $526,000 after purchasing an additional 181 shares in the last quarter. Finally, Jump Financial LLC purchased a new position in shares of Corteva during the second quarter valued at approximately $1,464,000. Institutional investors own 81.54% of the company’s stock.

Key Corteva News

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Corteva reported a stronger‑than‑expected Q1 (EPS and revenue beats), reaffirmed its 2026 outlook and said it remains on track for the planned 4Q‑2026 separation — fundamental results that support upside. Corteva Agriscience: Corteva Delivers Strong 1Q 2026, Reaffirms 2026 Outlook, On-Track for 4Q 2026 Separation
• Positive Sentiment: Jefferies raised its price target to $97, implying sizable upside versus current levels — a bullish analyst signal that can support the stock. Jefferies adjusts price target on Corteva to $97 from $95
• Neutral Sentiment: Management (CEO Chuck Magro and CFO David Johnson) will present at the BMO Global Farm to Market conference on May 14 — an event where management can reiterate guidance and answer analyst questions, but not an immediate catalyst. Corteva to Participate in BMO Global Farm to Market Conference
• Neutral Sentiment: Transcripts and the earnings presentation are now available for deeper review — useful for investors who want detail on margins, regional demand and guidance drivers. Corteva, Inc. (CTVA) Q1 2026 Earnings Call Transcript
• Negative Sentiment: BNP Paribas Exane lifted its target only to $77, which sits below current market levels and signals some analyst caution about upside from here — a factor contributing to downward pressure. BNP Paribas adjusts price target on Corteva to $77 from $74

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.